Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 10/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25032367 | 0.78 | CA12 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL838565 | 0.69 | CCR2 (0.37) | BRD4NR3C1PGRNR3C2AR | |
| SCHEMBL30832725 | 0.69 | L3MBTL1 (0.38) | BRD4NR3C1PGRNR3C2AR | |
| SCHEMBL29212355 | 0.67 | NR3C1 (0.51) | BRD4NR3C1PGRNR3C2AR | |
| SCHEMBL30184459 | 0.67 | NR3C1 (0.51) | BRD4NR3C1PGRNR3C2AR | |
| SCHEMBL29212344 | 0.66 | HTR6 (0.40) | — | |
| SCHEMBL29212291 | 0.66 | CA12 (0.36) | CA12CA1CA2CA9MAOA | |
| SCHEMBL31363366 | 0.65 | LRRK2 (0.34) | CA12CA1CA2CA9MAOA | |
| SCHEMBL30184522 | 0.65 | CA12 (0.35) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25033661 | 0.65 | CA12 (0.35) | CA12CA1CA2CA9MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968361-A | Compounds targeting p 53Y 220 mutants | 北京加科思新药研发有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024041503-A1 | COMPOUNDS TARGETING Y220C MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | CA12 3295/4885CA1 2782/4885CA2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.